Quadruplet verus sequential triplet induction therapy approaches to maximise response for transplant eligible (TE), newly diagnosed myeloma patients (NDMM) in the NCRI Myeloma XI trial
A salvage autologous stem cell transplant (ASCT2) induces superior overall survival following bortezomib-containing re-induction therapy for relapsed multiple myeloma (MM): Results from the Myeloma X (Intensive) Trial
ELOQUENT-2: Extended safety and efficacy follow-up of the phase 3, randomized, openlabel study of elotuzumab in combination with lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma
Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 Years and older with treatmentnaïve (TN) CLL/SLL (RESONATE-2TM)
Blocking CD62L inhibits CLL cell interaction with vascular endothelium; an effect that is augmented by ibrutinib
A CXCR4 inhibitor and Btk inhibitor ONO/GS-4059 are synergistic and result in loss of CLL cell migratory ability and survival
Potential benefit of higher dose daunorubicin in patients harbouring a FLT3-ITD mutation: Updated results of the AML17 trial
Conditional deletion of the HoxA cluster in MLL-AF9 is incompatible with leukaemia maintenance
Haemochromatosis is more than being a C282Y homozygote: The utility of NGS, using the 16 gene Disorders of Iron Regulation NGS Panel, and MPLA as routine diagnostic tools
Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory chronic lymphocytic leukemia: Results of a phase 3 randomized double-blind placebo-controlled study
Patient blood management in surgery - results of a UK National Comparative Audit in 2015
Idarucizumab reversal of anticoagulation in dabigatran-treated patients presenting with acute traumatic injuries: Interim results from the RE-VERSE AD Study
De-escalation of tyrosine kinase inhibitor treatment in chronic myeloid leukaemia patients with excellent molecular responses: Initial safety results from the DESTINY trial
Pregnancy outcome in women with myeloproliferative neoplasms in the United Kingdom
Comprehensive and effective biobanking for research into chronic myeloid malignancies
Identification of common and distinct epigenetic reprogramming properties of corebinding-factor fusion proteins
Targeted sequencing of 647 patients with myeloid malignancies, marrow failures and cytopenia: A prospective ‘real life’ analysis
Molecular signature of dormancy in CD34 + CD38- acute myeloid leukaemia cells
Reduced intensity conditioned allogeneic stem cell transplantation (RIC-Allo) as front-line therapy for mantle cell lymphoma (MCL): Results from the UK Phase II Mini Allo Study (CRUK: C7627/A9080)
Single UK centre outcomes of peripheral blood stem cell (PBSC) haploidentical transplantation
T-cell depletion with anti-thymocyte globulin (ATG) favours superior overall survival and lowers rates of relapse and GVHD when compared to alemtuzumab in patients undergoing allogeneic haematopoietic stem cell transplantation for myelofibrosis: A retrospective single centre analysis
Feasibility and optimal schedule of eculizumab in patients with haemolytic paroxysmal nocturnal hemoglobinuria (hPNH) with severe aplastic anaemia (SAA) prior to haemopoietic stem cell transplant (HSCT)
Outpatient hematopoietic grafting in patients with multiple sclerosis employing autologous non-cryopreserved peripheral blood stem cells: A feasibility study
Excellent outcomes following etoposidemelphalan autologous stem cell transplant in lymphoma patients unfit for standard BEAM conditioning
Current management and perinatal outcomes in women with idiopathic severe thrombocytopenia in pregnancy: National cohort study
Evolving antithrombotic treatment patterns in patients with newly diagnosed atrial fibrillation: UK findings from the GARFIELD-AF registry
Histone-associated thrombocytopaenia is a significant cause of thrombocytopaenia in critical illness
Extracellular histones promote prothrombin activation in the absence of phospholipids
Relationship between genotype and phenotype in ACTN1-related macrothrombocytopenia
Studying inherited diseases of the blood stem cell and its progeny through whole genome sequencing
Transfusion adverse events in patients with haemoglobinopathy - reports to the Serious Hazards of Transfusion UK Haemovigilance scheme 2010–2014
Laboratory surveys from UK Transfusion Laboratory Collaborative (UKTLC) confirm cause for concern
Improved compliance with guidelines for transfusion in haematology and the resulting blood reduction and cost savings through the implementation of an electronic blood ordering process including decision support
Transfusion for sickle cell disease in pregnancy: A single centre survey
Paroxysmal nocturnal haemoglobinuria screening practice from UK centres: A report from the UK PNH Network
Reference values in osmotic gradient ektacytometry for diagnosis of haemolytic anaemias due to red blood cell membrane defects
Human parvovirus B19 infection in patients with sickle cell anemia in Lagos State University Teaching Hospital (LASUTH), Ikeja, Lagos, Nigeria
An analysis of haematology patients admitted to ICU at Maidstone Hospital
Thrombelastographic and structural variations of human whole blood clot formation after ex vivo addition of s-nitrosoglutathione
Possible effect of ambient temperatures in transmission of malaria during off season
5-hydroxy-2-methyl-1,4-naphthoquinone (Plumbain from Plumbago zeylanica) is a potential drug candidate for attenuating drug induced hematotoxicity via modulation of antioxidant enzymes
Development of a long-acting granulocyte colony stimulating factor molecule
A retrospective analysis of the use of azathioprine for the treatment of immune thrombocytopenia (ITP)
A one year hospital based prospective study of sickle cell disease from one capital area of Kuwait by HPLC
Impact of immunoparesis and altered serum free light chain ratio (ASFLCR) on the progression of monoclonal gammopathy of undetermined significance (MGUS) in a district general hospital in the United Kingdom
Anti-coagulation ‘DATIX’ incident reporting audit
Clinical pharmacist-provided services in iron overloaded beta-thalassemia major children. A new insight to patient care
How do myeloma patients’ experiences before and during diagnosis compare to those for all cancers? Findings from secondary analysis of the National Cancer Patient Experience Survey 2014
Assessing the applicability of a blood test guide in Accident and Emergency to optimise blood test requesting and achieve value for money
Safety and diagnostic yield of splenic core biopsies performed under radiological guidance at a single centre
Review of use and implementation of the 2015 BCSH guidelines for the prophylaxis and treatment of tumour lysis syndrome in patients with haematological malignancy at University Hospitals Bristol
Analysis of cord blood units at different time points reveals gentle processing of cord blood by CellEffic CB
Eosinophilia: A three year survey in a tertiary centre
EphB4 enhances bone marrow stromal stem cell-mediated support of haematopoiesis
EphrinB1 expressing stromal cells exhibit an enhanced capacity for haematopoietic stem cell maintenance
Developing a telepathology service for rapid remote diagnosis in a resource challenged paediatric haemato-oncology unit in Malawi
PV: Poor Value?
Deficiency of vitamin D with hiperhomocysteinemia and essential thrombocytosis
Clinical associations with a markedly raised ferritin and their significance
The clinical utility of reticulocyte haemoglobin equivalent (Ret-He) and red cell distribution width (RDW-CV) in patients with polycythaemia vera
Acute thrombosis in a paediatric tertiary hospital; outcome and shortfalls
Eltrombopag use in severe ITP and beyond; a single centre cohort
Place of death in patients with haematological malignancy in the North-East of England: Where does this happen and what factors may influence this?
Platelet counting by immunophenotyping to overcome erroneous result due to platelet clumping
Investigating the appropriateness of oral iron therapy in older patients in primary care using routinely collected data
Mortality within 30 days of systemic anticancer therapy (SACT) - results of a multi-site audit following the NCEPOD model in the South Yorkshire region
The limitations of a generic chemotherapy consent form: Improving chemotherapy consent with the use of regimen-specific consent forms
The Latin American experience allografting patients with severe aplastic anaemia: Realworld data on the impact of stem cell source and ATG administration
Novel TUBB1 gene mutations in Turkish patients with macrothrombocytopenia
Some 80% of your patients with iliofemoral reflux post thrombotic syndrome might benefit from neovalve surgery
Critical care of patients with haematological malignancies - a retrospective analysis of one tertiary centre's experience
A gain-of-function variant in DIAPH1 is associated with heritable macrothrombocytopenia and sensorineural deafness
Developing haematological cancer services in Wales: Exploring options for ambulatory care
Prevalence of neutropenia in children by nationality
Use of rituximab for immune thrombocytopenic purpura - a single centre experience
Single centre experience of managing patients with Kikuchi-Fujimoto disease
Geophagia: A scientific approach to a historical practice to sustainably supplement iron to the diet in a rural community in Nepal
Improving the management of patients with a raised INR: a reaudit cycle and ongoing work
ENERCA: Towards a European Reference Network (ERN) in rare haematological diseases
A regional experience of ADAMTS13 testing, thrombotic thrombocytopenic purpura (TTP) diagnosis and outcome
Ferric carboxymaltose (Ferinject) use in the treatment of peri-partum anaemia is associated with relative hypophosphataemia
A high resolution genetic atlas of blood cell variation and function in humans
Outcomes for patients undergoing splenectomies in a district general hospital
Reticulocyte haemoglobin content (CHr) versus percentage hypochromic red cells (%HYPO): Stability determines suitability
Simultaneous testing of 45 genes underling a rare group of inherited bone marrow failure syndromes using Next Generation Sequencing; a review of the service to date
Congenital amegakaryocytic thrombocytopenia (CAMT) due to a novel deletion in the MPL gene identified by Next Generation Sequencing
CellCountr: An online workspace for streamlining the interpretation of bone marrow aspirates - case study of use in a teaching hospital diagnostic laboratory. https://cellcountr.com
The North of England haemato-oncology diagnostic service (NEHODS): A more devolved and inclusive approach to integrated reporting facilited by an IT system (Haemosys) networked to local information management systems (LIMS) in all participating regional hospitals
Age and gender effect on osteonecrosis in sickle cell disease
Reversal of coagulation markers in patients on dabigatran by prothrombin complex concentrate: A meta analysis
Prevalence of genetic variations in SERPINC1 gene in Indian deep vein thrombosis population with type I antithrombin deficiency
Normal pregnancy is associated with an increase in thrombin generation from the very early stages of the first trimester of pregnancy
Is there a need for a community anticoagulant monitoring service for the new direct acting oral anticoagulants?
Diagnosis and management of upper limb deep vein thrombosis in a district general hospital
Factors associated with activated protein C resistance in Indian patients with recurrent pregnancy loss
A small change makes a big difference: Not bridging ‘moderate risk’ AF patients halves use of LMWH for bridging at King's College Hospital
Primary thrombophilia in México XI. The activated protein C resistance phenotype is multifactorial
Single tertiary centre experience of treating thrombotic thrombocytopenic purpura between 2010–2015
Preventing hospital acquired thrombosis in medical patients at a district general hospital: Compliance with National Institute for Health and Care Excellence (NICE) guidance
External quality assurance (EQA) for thromboelastography (TEG) and thromboelastometry (Rotem)
Multiple phenotypic expression of Harris platelet syndrome
Validity of two-level Well's score in predicting lower limb deep vein thrombosis and the risk of developing hospital aquired thrombosis in hospitalised patients at National Hospital of Sri Lanka
Management and outcomes of deep vein thrombosis in injecting drug users: Is there a case for national guidance for this challenging scenario?
An unusual acquired coagulopathy
Risk of venous thromboembolism in care home residents
Global tests of blood clotting during asparaginase treatment for acute lymphoblastic leukaemia. Preliminary results of the GlobALL study
Is the factor VIII gene mutation c.1094A>G of clinical significance? Bleeding phenotype of a West Midlands patient cohort
Low-dose rituximab, eltrombopag and highdose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults
A single centre retrospective observational study assessing the incidence of hospital acquired thrombosis over an 8 year period from 2007 to 2014 spanning the introduction of mandatory venous thromboembolism (VTE) risk assessment data for adult patients admitted to hospital
Disease remission following the use of bortezomib in an adult patient with acute refractory thrombotic thrombocytopenic purpura
Effect of extremes of body weight on efficacy and safety of rivaroxaban in the treatment of venous thromboembolism; real life experience
A retrospective analysis of missed VTE assessments at Aintree University Hospital Trust
Prothrombin complex concentrate (PCC) related thrombosis: A systematic review
Predictors of major bleeding in adult immune thrombocytopenia (ITP)
Evaluation of a simplified procedure for EQA samples: First survey results for the point of care testing (POCT) INR EQA for CoaguChek, XS Plus & XS Pro users
Commutability of samples used to assess assays for direct oral anticoagulants (DOACS): Data from UK NEQAS for Blood Coagulation multicentre studies
Point of care d-dimer testing in practice: Survey results for d-dimer testing performed in patient care within the United Kingdom
Von Willebrand factor (VWF) assays and the diagnosis of von Willebrand disease (VWD). Who follows the guidelines?
Continued discrepancies between protein S activity assays?
Identifying factors that influence the agreement between platelet function tests in patients on P2Y12-inhibitors with a high bleeding risk
Venous thromboembolism in cardiac surgery: Comparing emergency to planned admissions over 5 years
Rituximab therapy as prophylaxis against thrombotic thrombocytopenic purpura: Comparison of standard and reduced dose regimens
Metabolism of coversin, a complement C5 inhibitor with applications in haematological diseases
An audit of thromboprophylaxis and venous thromboembolism rates in myeloma patients at King's College Hospital
Use of age adjusted d-dimer monitoring to assist the withdrawal of anticoagulation following unprovoked pulmonary embolism
Is there any clinical or biological difference that distinguishes recurrence from non-recurrence after idiopathic PE?
Venous thromboembolism incidence in ambulatory patients with pancreatic and endometrial cancer and association with Khorana Score
Severe antithrombin deficiency in pregnancy: How can adequate anticoagulation be achieved?
Von Willebrand testing - how useful is assessment of collagen binding in the diagnostic work-up of von Willebrand disease?
Do patients with ‘low VWF’ bleed?
Modified computer assisted strain gauge plethysmography (venometer V3) can safely decrease the need for compression ultrasound scanning in patients with suspected deep vein thrombosis
The use of age-adjusted d-dimer in patients over 50 years old presenting with a suspected deep vein thrombosis can safely decrease the need for compression ultrasound scanning
A survey of the management of venous thrombosis in cancer associated thrombocytopenia
Developing a new diagnostic algorithm for disseminated intravascular coagulation (DIC)
Continuation of eculizumab in atypical haemolytic syndrome (aHUS) patients without renal recovery or an identified complement defect
A retrospective analysis of correction studies in all patients with a prolonged activated partial thromboplastin time within the Belfast health and social care trust over a 3 year period
Effects of rivaroxaban and apixaban on routine coagulation screening tests
Evaluation of diagnostic delay in a cohort of individuals with acquired haemophilia A
Prothrombin complex concentrate (PCC) for reversal of vitamin K antagonists - a West of Scotland regional audit
Trends in oral anticoagulant prescriptions and major bleeding complications: A comparison of NHS CCG prescription data with cases from a prospective study (ORANGE) between October 2013 and June 2015
The relevance of placental infarction for subsequent pregnancies following stillbirth
Single UK tertiary neonatal unit experience of neonatal arterial thrombosis
Haemostatic and inflammatory changes following pre-eclampsia: Potential link with development of subsequent cardiovascular events?
Assessing the impact of direct oral anticoagulants on dental practitioners
Venous thrombotic events versus length of stay on warfarin, enoxaparin, rivaroxaban and apixaban
Use of direct oral anticoagulants in women of childbearing age: Data from the East Midlands registry
Method of renal function estimation influences accuracy of DOAC prescribing
Treatment of PE in the DOAC era: real-world experience
Differentiating acquired and congenital TTP: A case report demonstrating the limitations of ADAMTS13 inhibitor testing
Impedance platelet aggregometry for surveillance of ibrutinib therapy in chronic lymphocytic leukaemia
Splanchnic vein thrombosis (SVT) in patients with myeloproliferative (MPN) neoplasms
HIT at Southend: A cluster of cases associated with low molecular weight heparin use
Low molecular weight heparin (LMWH) and anti-Xa monitoring in pregnancy. A single centre experience
ThromboGenomics - a comprehensive highthroughput sequencing test for the diagnosis of inherited bleeding, thrombotic and platelet disorders
The impact of TTP specialist centres on patient survival and satisfaction
Superficial thrombophlebitis - treatment with rivaroxaban; a single centre experience
Assessment of deep venous thrombosis referrals in an ambulatory emergency care unit: A single centre study
The DAWN® 4S VTE module - an electronic tool and record for deep vein thrombosis (DVT) assessment, diagnosis, treatment and follow up
Validation of the use of age adjusted d-dimer cut off values to reduce the compression venous ultrasound rates in an acute ambulatory DVT service
A snapshot of anticoagulation in a district general hospital
Dilute Russell's viper venom time - potential use for the detection of apixaban and rivaroxaban predicted from interference in lupus anticoagulant testing
Hospital admission data on primary immune thrombocytopenia patients in the National Health Service: Findings using hospital episodes statistics & United Kingdom Immune Thrombocytopenia Registry linked data
Intravenous drug users presenting to an acute ambulatory DVT service: A single centre experience
Thrombi form faster and are more resistant to lysis at low haematocrit
Outcomes of patients treated for cancer or chemotherapy associated venous thromboembolism and effectiveness of secondary prevention
Platelet activation and aggregation is modulated by the Hodgkin lymphoma ‘secretome’
DOACs: Common and uncommon errors. A brief patient safety intervention and review
The introduction of lab based TEG testing: Could South Tees NHS Foundation Trust introduce an individualised goal-directed therapy with regards to effective blood management
Safety of plasma exchange in the treatment of thrombotic microangiopathies
Treatment pattern of immune thrombocytopenia over time: Findings from the United Kingdom Immune Thrombocytopenia (UK ITP) Registry
Correlating FMC7 and CD20 expression in B cell malignancies
A specific ITK inhibitor, ONO-7790500, represses TCR signalling in T-cell lines: Potential for treatment of peripheral T-cell lymphoma
Mir-363 is a potential biomarker of the tumour microenvironment in chronic lymphocytic leukaemia
TBK1/IKKε inhibitors target a subset of diffuse large B-cell lymphoma
Combinations containing the azaanthracenedione pixantrone show pre-clinical activity in diffuse large B-cell lymphoma (DLBCL)
Impact of adhesion molecules expression on nodal and extra-nodal involvement in chronic lymphocytic leukemia
Characterisation of telomere dynamics in lymphocyte subsets from chronic lymphocytic leukaemia patients
Curcumin loaded biocompatible electrospun polymer mats for the treatment of CTCL skin lesions
Impact of the apoptotic regulator DRAK2 in chronic lymphocytic leukemia
Differences in phenotype and immune function of lymph node and peripheral blood derived CLL cells are linked to transendothelial migration
Comparison between fusion transcripts and leukemia-associated immunophenotypes as markers of minimal residual disease in B-precursor acute lymphoblastic leukemia
Analysis of the MM.1S multiple myeloma cell line reveals a distinct phenotypic and genetic architecture including a pre-existing MM.1Rlike glucocorticoid resistant sub-clonal population
Characterising the immune phenotype of paediatric acute lymphoblastic leukaemia patients during induction chemotherapy
T lymphocyte reconstitution during induction chemotherapy in paediatric B-cell acute lymphoblastic leukaemia
Preclinical investigation and validation of a second generation CD19 directed chimeric antigen receptor (CAR), to target diffuse large B-cell lymphoma (DLBCL) for use in a phase 1 clinical trial
The presence of MYD88 L265P in non-IgM lymphoplasmacytic lymphoma: Implications for diagnosis and therapy
Characterisation of ibrutinib-resistance in B lymphoma cells
Dysregulation of CCN1 expression in conjunction with increased expression of p21CIP1 and p27KIP1 implicated in mantle cell lymphoma progression
CD319 and CD38 expression patterns in Waldenstrom's macroglobulinaemia (WM), myeloma and MGUS: Implications for antibody therapy
Pyrrolobenzodiazepine (PBD) monomers are cytotoxic and produce inhibitory effects on NF-κB in CLL and multiple myeloma
Cold agglutinin disease is a phenotypically distinct clonal B-cell disorder
A comparison of PCR methods for the detection of MYD88 L265P mutations in a diagnostic setting
Molecular classification of DLBCL: An improved prognostic and diagnostic tool compared to standard immunohistochemistry
Efficacy and safety of single-agent ibrutinib in rituximab-refractory patients with Waldenström's macroglobulinemia (WM): Initial results from an international, multicenter, open-label phase 3 substudy (iNNOVATETM)
Efficacy of different chemotherapy regimens in primary mediastinal large B-cell lymphoma
What is the best route for methotrexate delivery to reduce the incidence of central nervous system relapse in diffuse large B-cell lymphoma? A review of our practice at University Hospital Aintree, Liverpool
Efficacy and safety of RCEOP chemotherapy in patients with diffuse large cell lymphoma (DLCL) not fit for anthracyclines are comparable to RCHOP
An analysis of cost savings achieved through the practice of vial sharing for patients receiving bortezomib (Velcade®) containing regime in multiple myeloma in a district general hospital (DGH) haematology unit over a two year period
Diagnosing light chain (AL) amyloidosis on temporal artery biopsies for suspected giant cell arteritis
Audit of central nervous system (CNS) prophylaxis in diffuse large B cell lymphoma (DLBCL) in adult patients in West of Scotland
A comparative retrospective analysis of the frequency of microbiologically confirmed respiratory tract infections in patients receiving rituximab maintenance therapy for B cell - non Hodgkins lymphoma
Clinical, morphological and laboratory characteristics of patients with indolent non-Hodgkin's lymphoma, markers of viral hepatitis with and without markers of hepatitis C
Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma
The NCRI Myeloma XI trial for newly diagnosed symptomatic multiple myeloma (NDMM); second primary malignancy (SPM) incidence when lenalidomide is used as an induction and maintenance treatment option
Estrogen receptor beta (ERb) expression in diffuse large B cell lymphoma (DLBCL): A predictor of poor outcome
Real world experience of ibrutinib in mantle cell lymphoma - prospective multi-centre data from 61 patients treated for MCL with ibrutinib (single agent) via the expanded access programme in Great Britain and Ireland
Experience of lenalidomide use in the treatment of myeloma at North Bristol NHS Trust - increasing number of dose modifications is associated with increased overall survival
The addition of rituximab to CODOX-M & IVAC in first line therapy of poor risk Burkitt lymphoma (IPI 3–5) yields an excellent outcome: A phase 2 UK NCRI/Bloodwise Trial (LLR 04058)
Front line therapy with R-CODOX-M & R-IVAC in poor risk diffuse large B cell lymphoma (IPI 3–5) yields a good outcome without transplantation: A phase 2 UK NCRI/Bloodwise Trial
A retrospective analysis of therapy and outcomes in post-transplant lymphoproliferative disorder (PTLD) over a 15-year period at a major UK transplant centre
Incidence of occult systemic lymphoma in patients with primary central nervous system lymphoma (PCNSL)
Plasma cell dyscrasia and an increased risk of fracture: Evidence from hospital episodes statistics
Clinical, morphological and laboratory characteristics of patients with diffuse large Bcell lymphoma non-Hodgkin's lymphoma with markers of hepatitis C (HCV) (DLBCL+C) and without markers of hepatitis C (DLBCL- C)
Audit of thromboprophylaxis for patients with multiple myeloma on treatment with immunomodulatory drugs
Intrathecal chemotherapy prophylaxis for diffuse large B cell lymphoma (DLBCL): Real-life clinical practice in the face of conflicting guidelines and a weak evidence base
Is toxicity and inpatient admission time reduced with recently introduced GDP salvage chemotherapy compared to IVE and DHAP chemotherapy? A retrospective review of relapsed and refractory lymphoma patients in the Northern region of England
Single centre experience of managing patients with double hit lymphoma (DHL)
Single centre experience of lenalidomide in multiply relapsed and or refractory lymphomas
Bortezomib vial sharing in multiple myeloma (MM) treatment: What is needed for this innovation to succeed?
Reversal of multiple myeloma (MM) associated pulmonary hypertension (PH) in 2 patients
The cost effectiveness of idelalisib in chronic lymphocytic leukaemia in England and Wales
Activity of idelalisib in high-risk follicular lymphoma with early relapse following front line immunochemotherapy
Minimal residual disease analysis in patients with follicular lymphoma treated with obinutuzumab plus bendamustine versus bendamustine alone in GADOLIN, a phase III study of relapsed/refractory indolent non-Hodgkin lymphoma
Population-based study of patients with mantle cell lymphoma; era by era improvement in survival mediated by first-line rituximab and autologous stem cell transplantation
A review of the management of elderly Hodgkin lymphoma in North Glasgow
An updated survival analysis from the CLL11 study in patients with chronic lymphocytic leukaemia treated with obinutuzumab or rituximab in combination with chlorambucil versus chlorambucil alone
Focal segmental glomerulosclerosis: A paraneoplastic phenomenon of mantle cell lymphoma
High thrombotic risk of T-lymphoblastic lymphoma treated with intensive asparaginase containing ALL regimes; retrospective, observational data from a single centre
Ibrutinib for relapsed/refractory CLL: A UK and Ireland survival analysis
Bortezomib thalidomide dexamethasone (VTD) induction chemotherapy prior to autologous stem cell transplant in multiple myeloma: An experience in actual clinical practice
Subcutaneous rituximab can be safely administered without pre-medication
A phase 2 study of idelalisib monotherapy in previously untreated patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials
Treatment and outcomes of secondary CNS lymphoma in a tertiary referral centre
Results of a phase III randomized, controlled study evaluating the efficacy and safety of idelalisib in combination with ofatumumab (OFA) for previously treated patients with CLL
Audit of the use and response rate of pomalidamide in clinical practice: A large DGH experience
Overall survival analysis adjusting for treatment effect after crossover in a phase 3 study evaluating idelalisib in combination with rituximab in relapsed CLL
Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory iNHL and CLL
Idelalisib efficacy and safety in follicular lymphoma patients from a phase 2 study
Idelalisib monotherapy and durable responses in patients with relapsed or refractory marginal zone lymphoma (MZL)
Quality of life (QoL) benefits of idelalisib with rituximab for patients with previously treated chronic lymphocytic leukaemia
A dramatic response to lenalidomide based chemotherapy in a patient with multiple relapsed GCB-subtype diffuse large B cell lymphoma post allogeneic stem cell transplant
Global mantle cell lymphoma (MCL) named patient program (NPP) experience in >790 patients treated with ibrutinib
Idelalisib monotherapy and durable responses in patients with relapsed or refractory small lymphocytic lymphoma (SLL)
Idelalisib monotherapy results in durable responses in patients with relapsed or refractory Waldenstrom's macroglobulinemia (WM)
Reduction in serum paraprotein level due to curcumin in a patient with asymptomatic myeloma
An update on prospective audit of rivaroxaban as prophylaxis and treatment during myeloma therapy with immunomodulatory drugs (IMiDs) at East Kent Hospitals University NHS Foundation Trust
Hepatotoxicity with pegylated-asparaginase in acute lymphoblastic leukaemia is influenced by raised body mass index
Long-term results of treatment of diffuse large B-cell lymphoma with markers of hepatitis C (DLBCL+C) and B-cell diffuse large cell lymphoma without markers of hepatitis C (DLBCL-C) and role of antiviral therapy for hepatitis C virus (HCV)
Lenalidomide: the Northern Ireland experience 2009 - 2014
The Leeds Haematological Malignancy Diagnostic Service Outreach postal monitoring service for patients with indolent Blymphoproliferative and plasma cell disorders: 10-year evaluation of laboratory parameters and symptom self-assessment for early identification of disease progression
Minimal residual disease predicts outcome in transplant ineligible myeloma patients: Results from the UK NCRI Myeloma XI trial
Histopathological features and poor clinical outcomes in a predominantly human immunodeficiency virus negative (HIV-) group of patients with plasmablastic lymphoma (PBL): A population based retrospective study
Tumour lysis risk assessment and prophylaxis for high grade lymphoma in a large university hospital - an audit against BCSH Guidelines
Avoiding a sticky end: The importance of considering cryoglobulins and cryofibrinogens
The cost of myeloma: A gap analysis in the diagnostic work-up of multiple myeloma at Gloucestershire Hospitals NHS Foundation Trust
Significance of early interim PET results in advanced Hodgkin lymphoma treated intensive program EACOPP-14
Patients in the MRC Myeloma XI trial receiving induction chemotherapy for newly diagnosed multiple myeloma containing dexamethasone at full or moderated dose have significantly reduced half-life of IgG
Primary central nervous system lymphoma in adults: Clinicopathological features and outcomes in a tertiary centre in Malaysia
Pattern of infections in patients with multiple myeloma: A single centre experience in a developing country
Brentuximab vedotin as a bridge to transplant in classical Hodgkin lymphoma: Single tertiary centre real-world experience
Hepatitis B reactivation in patients receiving R-CHOP: Delayed reactivation and infrequent breakthrough on lamivudine prophylaxis
Diagnosis and management of CLL patients - single centre experience
Nodular lymphocyte predominant Hodgkin lymphoma: A retrospective review of 30 consecutive cases managed through the Norfolk and Waveney MDT
A single centre experience of DPACE-based therapy with lenalidomide or thalidomide ± bortezomib prior to autologous transplant in myeloma
The efficiency and long-term results of treatment of patients with indolent lymphoma with hepatitis C virus and without hepatitis C virus
Absolute differential between urinary protein creatinine ratio (PCR) and albumin creatinine ratio(ACR): An early warning indicator for multiple myeloma
Pattern of lymphoma in the University of Calabar Teaching Hospital, Calabar, Nigeria
An ongoing multinational observational study in multiple myeloma (PREAMBLE): Preliminary report on patient survival
Global chronic lymphocytic leukaemia (CLL) named patient program (NPP) experience in > 2900 patients treated with ibrutinib
A retrospective review of CNS prophylaxis in diffuse large B cell lymphoma in two district general hospitals
Evolution of the first line treatment of multiple myeloma in a district general hospital setting - a retrospective review of overall survival and time to second treatment
Back door lymphoma: Protean presentation of patients with newly diagnosed lymphoma and the implications for newly proposed NICE guidance
The use of CD200 antigen to assist in differentiating between chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL)
Variegate presentation of lymphoma patients contributes to the risk of a delayed diagnosis
Central nervous system involvement in chronic lymphocytic leukaemia
Rationalizing the use of intravenous immunoglobulin replacement in secondary antibody deficiency
The LLR TAP IcICLLe trial assessing biological response to ibrutinib in CLL: Immediate disease redistribution precedes cell cycle arrest by 2 weeks with reduced bone marrow infiltration by 6 months
Assessment of DNA damage and DNA damage response and repair in dormant leukaemic cells
Basal expression of erythroid regulators mRNA of β-thalassemia/Hb E erythroblasts
Reduced Fas-associated phosphatase-1 expression in patients with acute myeloid leukaemia
CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression
Resazurin/resorufin inhibits protein kinase CK2 and exhibits anti-leukemic effect in vitro and in vivo
The impact of biomarkers on outcomes of 203 Taiwanese patients with primary myelofibrosis: Endogenous erythroid colony growth and CALR mutation are independent favorable predictors
Integrated analysis of the biological and molecular effects of the epigenetic modifying agent romidepsin in MDS and AML
DNA damage response in dormant AML cells
Small molecule Axl inhibitor BGB324 inhibits primary chronic phase chronic myeloid leukaemia (CML) cell function and viability
T cell subsets do not alter on decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: Data from the DESTINY trial
Uncovering the BCR-ABL1 tyrosine kinase independent signature in chronic myeloid leukaemia stem cells
Small molecule inhibitors against PI3K/Akt/mTOR and NF-kB signaling pathways as a combinatorial approach in acute myeloid leukemia treatment
MicroRNAs that affect the Fanconi anaemia (FA)/BRCA pathway are downregulated in imatinib-resistant patients without detectable BCR ABL kinase domain mutations
Germline heterozygous DDX41 variants account for a subset of familial myelodysplasia and acute myeloid leukaemia
Ribosomal protein S6 dephosphorylation is a rapid broad-spectrum biomarker for therapeutic targeting of leukaemia cells
Mebendazole: A candidate FDA approved drug for repurposing in leukaemia
Identifying genes and pathways deregulated in chronic myeloid leukaemia stem cells through meta-analysis of transcriptomic data
Germline mutations of hTERT in myelodysplastic syndromes are associated with shortened telomeres but are not associated with increased cytogenetic abnormalities
Outcome of solitary plasmacytoma
Platelet count predicts Janus Kinase 2 status at presentation of polycythaemia vera
An analysis of the cost savings achieved through practice of vial sharing for patients on azacitidine (Vidaza®) treatment for myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML with 10–29% blasts) and acute myeloid leukaemia (AML with 20–30% blasts) in a district general hospital (DGH) haematology unit over a 2 years period
Observational study of multiple myeloma in Latin America
A 48-year-old man with thrombocytopeniaabsent-radius syndrome and pancytopenia
Prospective study of trough imatinib levels in newly diagnosed chronic myeloid leukaemia (CML) patients and its correlation with response
Pegylated-interferon alfa-2a treatment is safe and effective for pregnant women with essential thrombocythaemia
Reduction in gram negative rod sepsis rate in intensively treated patients with acute myeloid leukaemia achieved through identification of unexpected potential environmental source: A successful root-cause analysis
Therapeutic leukapheresis in Chinese patients with hyperleukocytosis and leukostasis
Patient outcomes from a nurse-managed home azacitidine administration programme: A single centre experience
Risk of cardiovascular disease (CVD) in chronic myelogenous leukemia (CML) patients from community-based oncology practices
Status of persistent, grade 1/2 imatinib-related adverse events (AEs) in chronic phase chronic myeloid leukemia (CML-CP) patients after switching to dasatinib (DASPERSE/CA180–400)
The use of ruxolitinib in the treatment of myelofibrosis: A review of clinical practice and response in a single teaching hospital
Thiamine deficiency is uncommon in patients with myeloproliferative neoplasms
Factors predicting survival in adult acute myeloid leukaemia: The experience of a district general hospital
The analyses of efficacy and tolerability of ruxolitinib in myelofibrosis patients - our experience
Danazol as first-line therapy for myelodysplastic syndromes
Multilineage involvement and not multilineage dysplasia differentiates more precisely two basic biological categories of acute myeloid leukaemias
Long term follow up of patients with acute promyelocytic leukaemia (APL) treated in a tertiary referral centre: the South Wales experience (2008–2014)
Morbidity and mortality outcomes in acute myeloid leukaemia (AML) patients treated with FLAG or FLAG-IDA chemotherapy; a single centre experience
Clinical details are vital for the effective application of a targeted CALR mutation service for JAK2 negative referrals
Ruxolitinib in myelofibrosis; a single-centre experience
Single centre review of chronic myeloid leukaemia (CML) patients: Prognostics, European Leukaemia Net (ELN) response assessments, tyrosine kinase inhibitor (TKI) tolerability and outcomes
Impact of unsuccessful karyotyping in AML - a single centre study
Engraftment post autologous stem cell transplant for multiple myeloma is unaffected by length of stem-cell storage. Experiences from the Royal Marsden Hospital, UK
Balancing therapeutic impact of treatment strategies with quality of life and pain experience in multiple myeloma: New insights into influence of genetic variants
An experience with ruxolitinib, a Janus Kinase 1 and 2 inhibitor, in the management of patients with myeloproliferative neoplasms
Chronic myeloid leukaemia patients with the e14a2 BCR-ABL transcript type have a distinct phenotype with a trend to improved major molecular response rates
To bleed or not to bleed: Identifying the clinical significance of platelet function abnormalities in myelodysplastic syndrome (MDS)
Clinico-haematological profile in myelodysplastic syndromes (MDS) patients from a single tertiary care cancer center in India
CNS demyelination in patients on nilotinib treatment for CML
A prospective multicentre study of the demographic, molecular and clinical landscape of myeloproliferative neoplasm in a developing country
A review of new diagnoses of haematological malignancies within the Leicestershire, Northamptonshire and Rutland region
Implementation of high throughput sequencing in an integrated laboratory: Experience from the Haematological Malignancy Diagnostic Service (HMDS)
Pegylated interferon alpha-2a in high risk myeloproliferative neoplasms: A safe, effective and well tolerated alternative to hydroxycarbamide
Molecular targets to guide tyrosine kinase inhibitor therapy in chronic myeloid leukaemia
Challenges associated with mutational screening of suspected myeloproliferative neoplasms in a regional diagnostic laboratory
FLAG-lite regimen is effective bridging salvage chemotherapy for relapsed/refractory acute myeloid Leukaemia - a single centre experience
Single centre experience of treating aplastic anaemia with anabolic steroids
Low level laser therapy in the treatment of chemotherapy-induced mucousitis is an upcoming and successful intervention in modern medicine. A small group of forty patients have been studied to identify the effectiveness of this treatment in the bone marrow transplant setting
Clinical trials in multiple myeloma (MM): A survey of recruitment figures, screening failures and interventions
Unlocking the potential of anticoagulation nurse specialists
Holistic needs assessment of physical and psychosocial difficulties experienced in a cross section of multiple myeloma and other plasma cell dyscrasia patients
Haematology outreach: The impact on capacity, savings and quality
Second line therapy for children with persistent or chronic ITP: Results from the UK Paediatric ITP Registry
The impact of immune thrombocytopenia on health-related quality of life in children
Central nervous system imaging findings of patients with Fanconi aplastic anemia
Chediak-Higashi syndrome - too little too late?
Single dose rasburicase reduces the financial toxicity and prevents tumour lysis syndrome in children with high tumour burden
Presentation, course and outcome of langerhans cell histiocytosis in children
Leukostasis and tumor lysis syndrome in children's leukaemia admitted to an intensive care unit
Review of an internal quality assurance programme for transcranial doppler (TCD) screening in children with sickle cell disease. Experiences from Bart's Health NHS Trust
Haemophagocytic lymphocytic histiocytosis - a single centre review of cases
Clinical and genetic features of patients with Fanconi anemia in Lebanon and a report on two novel mutations in the FANCA gene
Haemoglobinopathies in the Northern Darfur state, stratified by tribes and ages
Comparison of iron chelation efficacy between deferiprone and deferasirox in non-transfusion dependent thalassaemia
Hematological abnormalities and serum cobalamin: Correlation with severity of neurological manifestations in vitamin B12 deficiency-related myeloneuropathies
Fanconi syndrome and metabolic acidosis in association with deferasirox (Exjade) in children with β thalassaemia major: Two cases and literature review
Treating sickle cell acute pain crisis at a busy London emergency department
Investigation of anaemia in patients admitted to a Medicine of the Elderly Unit
Diagnostic challenges in the evaluation of hemoglobinopathies in an under resourced setting
Spectrum of haemoglobinopathies detected by capillary electrophoresis in East Kent
Fat embolism syndrome in 3 patients with sickle cell disease
The impact of an integrated social care provision approach on admission data in sickle cell patients: An evaluation
Barriers affecting the nutritional management of sickle cell patients in the UK: Findings from a national dietitians survey
How to improve time to analgesia in sickle cell disease drop-in services
Use of automated red cell exchange transfusion in the management of stuttering priapism in sickle cell disease
Hydroxyurea and sickle cell disease: Do we need to reach the maximally tolerated dose (MTD)?
Co-incidence of iron deficiency/overload in beta thalassaemia trait
Higher dose hydroxyurea/hydroxycarbamide therapy for sickle cell disorders in childhood: The experience of Alder Hey Children's Hospital
Exploring chronic pain in thalassaemia patients
Sickle cell acute painful episode management at a district general hospital setting
The impact of a nurse led clinic to improve patient compliance with hydroxycarbamide - a retrospective analysis
Effect of automated red cell exchanges on oxygen saturation on air, blood parameters and length of hospitalization in sickle cell disease patients with acute chest syndrome
Serum cortisol level and its correlation with liver and cardiac iron concentration with clinical symptoms and other endocrinopathies in transfusion dependent beta thalassaemia patients
Implantable dual lumen ports are associated with an increased risk of right atrial thrombosis in patients with sickle cell disease
A life-threatening autoimmune hemolytic anemia in a patient with newly-diagnosed pulmonary sarcoidosis
An unusual case of methaemoglobinaemia in pregnancy
Decreased SOD2 mRNA levels in peripheral blood cells from steady-state sickle cell disease patients
Response of different thalassaemia intermedia genotypes to hydroxyurea therapy
Annual review of transfusion targets in regularly transfused paediatric and adult sickle cell patients. Experiences from Bart's Health NHS Trust
A novel cause of ineffective erythropoiesis; SPTA1 mutations
Seroepidemiology of hepatitis B, C & HIV among blood donors in Jos, North-Central Nigeria
Public involvement in clinical research: Lessons from a cluster-randomised trial
Sustained effect on compliance with transfusion guidelines of a combination of direct feedback about practice and an electronic decision support process
A descriptive single centre experience of the management and outcome of maternal alloantibodies in pregnancy
The impact of the implementation of an electronic prescribing system on the use of single unit transfusions in an acute haematology ward
A comparative retrospective review of blood usage since the implementation of a single unit transfusion policy for haematology inpatients
Post transfusion purpura followed by immune thrombocytopenia
Serious Hazards of Transfusion (SHOT) scheme analysis of cumulative errors in incorrect blood component transfused haemovigilance reports 2013–2014
Changing patterns of off-licence use of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of major haemorrhage
Pre-transfusion testing and confirmation of patient ABO group for first time transfused patients
A red cell dosage calculator could promote single unit red cell transfusion, prevent overtransfusion and reduce red cell usage
Optimisation of preoperative anaemia in patients undergoing elective cardiac surgery
Tertiary neonatal single centre experience of fresh frozen plasma transfusion - an audit of current practice
Does the age of platelet product transfused affect the time to next platelet transfusion? A retrospective review of 3636 platelet transfusions given to haematology patients
Real time monitoring method for iron chelation therapy
Pitfalls in pre-procedure optimisation of platelet transfusion
Single unit blood transfusion in the acute haematology setting
Hyperhaemolysis in sickle cell disease is not necessarily a transfusion reaction
Effective use of oral ribavirin for respiratory syncytial viral infections in allogeneic haematopoietic stem cell transplant recipients
Is there any difference in line infection rates between Hickmann and internal jugular/subclavian central lines in stem cell transplant patients?
Hematopoietic stem cell transplant activity in Latin America: Predominant increase in autologous and modest increase in allogeneic HCT with high use of unrelated cord blood grafts
Outpatient haploidentical peripheral blood stem-cell transplantation with post-transplant cyclophosphamide in children and adolescents
Donors who are heavier than their recipient, male, have a BMI > 30 or are aged < 40 provide the best chance of meeting requested cell dose for PBSC transplantation
Audit of use of plerixafor for stem cell mobilisation prior to haematopoietic stem cell transplant
Outcomes following salvage autologous stem cell transplant (ASCT2) vs low dose alkylating consolidation (non-transplant consolidation NTC) therapy following bortezomib-containing re-induction for relapsed multiple myeloma (MM) may be dependent on age and symptomatic status initiation of re-induction: Results from the Myeloma X (Intensive) Trial
Donor cell t(8:21) AML after allogeneic unrelated donor hematopoietic stem cell transplantation for infant ALL
Prospective review of therapeutic antifungal therapy in HSCT and acute leukaemia patients
Shared post-transplant care: Improving the effectiveness of service provision
Anti-phospholipase A2 receptor (Anti-PLA2R) antibody positive-nephrotic syndrome as a manifestation of multi-system, immunemediated complications post allogeneic stem cell transplant: A case report
Response to hepatitis B virus vaccination in patients after peripheral blood stem cell transplantation: A single centre experience
An audit of stopping antifungal prophylaxis post allogeneic stem cell transplantation
Subarachnoid hemorrhage (SAH) as the initial presentation of polycythemia vera
Abuse in the use of benzodiazepins with vitamin D deficiency
Frequency of platelet function disorders in patients presenting with bleeding
Autoimmune heparin-induced thrombocytopenia: A case report
Management and outcome of pregnancy in a woman with benign hypergammaglobulinemic purpura
Tissue factor and inflammatory cytokines in urine and plasma of catheterised patients managed using valves or free drainage
Immunophenotypic analysis of haematological malignancies in a Pakistani population
A workflow to demonstrate architecture and number of T-cell subsets in B-cell non-Hodgkin's lymphoma by multiplex immunohistochemistry
A case demonstrating the efficacious use of PCR in distinguishing between cutaneous CD30 positive lymphoproliferative disorders (cutaneous ALCL, lymphomatoid papulosis, cutaneous deposition of systemic ALCL) and transformed mycoses fungoides (MF)
Primary bone marrow diffuse large B-cell lymphoma presenting with an isolated thrombocytopenia: A case report
Paraproteinameia - a rare cause of a demyelinating neuropathy
Clinico-pathological profile of primary GI lymphoma - study from a single centre in Nepal
Retinal microinfarcts, an unusual ocular presentation in chronic lymphocytic leukaemia
10 cases of hematologic malignancy that caused gastrointestinal perforation - experience in our department
Extremely rare case, extranodal lymphoma of prostate
Diagnosis of splenic lymphoma with circulating villous lymphocytes
Hematological malignancies in HIV/AIDS
Diagnosis of extramedullary plasmablastic plasma cell myeloma
81 year-old lady presenting with anaemia and cerebellar syndrome
Wilms tumor-1 (WT1) gene mutation: a prevalence study in acute myeloid leukemia
Acute lymphoblastic leukaemia (ALL) transformed from chronic phase chronic myeloid leukaemia (CML) in major molecular response (MMR) on tyrosine kinase inhibitors (TKIs) for 5 years
Primary myelofibrosis (PMF) with co-existent paroxysmal nocturnal haemoglobinuria (PNH)
Hypereosinophilic syndromes FIP1L1/PDGFRA fusion gene NEGATIVE - hematological remission on imatinib mesilate
A case of acute myeloid leukemia developing after treatment for brucellosis with pancytopenia
Haemoglobin H disease detected during presentation of idiopathic thrombocytopenic purpura in a 14-month old boy
Quality of life in adults with sickle cell disease
Pregnancy associated sickle hepatopathy successfully treated with exchange transfusion
Identifying and prioritising treatment uncertainties in blood transfusion through the James Lind Alliance
Ensuring the correct use of irradiated blood products (IRRBP) following immunosuppressive medication: An experience across two Trusts
Experience of therapeutic plasma exchange in patients with severe fever with thrombocytopenia syndrome
Investigating the efficacy of treatment options for haematological diseases: Umbilical cord blood transplants against alternative haemopoietic stem cell sources
High dose melphalan and autologous stem cell transplantation following urinary bladder reconstruction with ileum: Measures to minimise mucositis